vs
Clearfield, Inc.（CLFD）与CytomX Therapeutics, Inc.（CTMX）财务数据对比。点击上方公司名可切换其他公司
Clearfield, Inc.的季度营收约是CytomX Therapeutics, Inc.的1.8倍（$34.3M vs $18.7M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -1.8%，领先1.0%），Clearfield, Inc.同比增速更快（-3.2% vs -25.7%），Clearfield, Inc.自由现金流更多（$-2.4M vs $-15.8M），过去两年Clearfield, Inc.的营收复合增速更高（-3.5% vs -15.9%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
CLFD vs CTMX — 直观对比
营收规模更大
CLFD
是对方的1.8倍
$18.7M
营收增速更快
CLFD
高出22.5%
-25.7%
净利率更高
CTMX
高出1.0%
-1.8%
自由现金流更多
CLFD
多$13.4M
$-15.8M
两年增速更快
CLFD
近两年复合增速
-15.9%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $18.7M |
| 净利润 | $-614.0K | $-154.0K |
| 毛利率 | 33.2% | — |
| 营业利润率 | -5.3% | -6.9% |
| 净利率 | -1.8% | -0.8% |
| 营收同比 | -3.2% | -25.7% |
| 净利润同比 | 67.8% | 97.6% |
| 每股收益（稀释后） | $-0.04 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDCTMX
| Q4 25 | $34.3M | — | ||
| Q3 25 | $23.4M | — | ||
| Q2 25 | $49.9M | $18.7M | ||
| Q1 25 | $47.2M | $50.9M | ||
| Q4 24 | $29.7M | $38.1M | ||
| Q3 24 | $5.6M | $33.4M | ||
| Q2 24 | $48.8M | $25.1M | ||
| Q1 24 | $36.9M | $41.5M |
净利润CLFDCTMX
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $1.6M | $-154.0K | ||
| Q1 25 | $1.3M | $23.5M | ||
| Q4 24 | $-1.9M | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | $-447.0K | $-6.5M | ||
| Q1 24 | $-5.9M | $13.8M |
毛利率CLFDCTMX
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
营业利润率CLFDCTMX
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | — | ||
| Q2 25 | 3.0% | -6.9% | ||
| Q1 25 | 0.6% | 44.4% | ||
| Q4 24 | -6.9% | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | -4.7% | -33.7% | ||
| Q1 24 | -26.4% | 28.1% |
净利率CLFDCTMX
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | — | ||
| Q2 25 | 3.2% | -0.8% | ||
| Q1 25 | 2.8% | 46.2% | ||
| Q4 24 | -6.4% | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | -0.9% | -26.0% | ||
| Q1 24 | -16.0% | 33.3% |
每股收益（稀释后）CLFDCTMX
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | — | ||
| Q2 25 | $0.11 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.40 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $49.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $249.7M | $119.9M |
| 总资产 | $268.1M | $175.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFDCTMX
| Q4 25 | $96.4M | — | ||
| Q3 25 | $106.0M | — | ||
| Q2 25 | $117.2M | $49.0M | ||
| Q1 25 | $112.0M | $47.6M | ||
| Q4 24 | $113.0M | $38.1M | ||
| Q3 24 | $129.0M | $40.6M | ||
| Q2 24 | $123.8M | $43.2M | ||
| Q1 24 | $142.9M | $36.2M |
总债务CLFDCTMX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
股东权益CLFDCTMX
| Q4 25 | $249.7M | — | ||
| Q3 25 | $256.2M | — | ||
| Q2 25 | $264.5M | $119.9M | ||
| Q1 25 | $265.9M | $25.0M | ||
| Q4 24 | $267.4M | $-456.0K | ||
| Q3 24 | $275.8M | $-23.5M | ||
| Q2 24 | $274.6M | $-31.2M | ||
| Q1 24 | $279.2M | $-31.7M |
总资产CLFDCTMX
| Q4 25 | $268.1M | — | ||
| Q3 25 | $306.2M | — | ||
| Q2 25 | $314.7M | $175.1M | ||
| Q1 25 | $310.9M | $98.5M | ||
| Q4 24 | $303.2M | $120.5M | ||
| Q3 24 | $315.3M | $139.0M | ||
| Q2 24 | $318.1M | $159.2M | ||
| Q1 24 | $315.4M | $184.7M |
负债/权益比CLFDCTMX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-15.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-15.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -84.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-77.7M |
8季度趋势，按日历期对齐
经营现金流CLFDCTMX
| Q4 25 | $-1.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.9M | $-15.8M | ||
| Q1 25 | $3.0M | $-21.0M | ||
| Q4 24 | $7.2M | $-19.9M | ||
| Q3 24 | $22.2M | $-20.7M | ||
| Q2 24 | $4.0M | $-19.5M | ||
| Q1 24 | $-5.7M | $-26.0M |
自由现金流CLFDCTMX
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-15.8M | ||
| Q1 25 | $654.0K | $-21.2M | ||
| Q4 24 | $5.1M | $-20.0M | ||
| Q3 24 | $18.2M | $-20.7M | ||
| Q2 24 | $2.8M | $-19.6M | ||
| Q1 24 | $-7.7M | $-26.2M |
自由现金流率CLFDCTMX
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -84.6% | ||
| Q1 25 | 1.4% | -41.6% | ||
| Q4 24 | 17.1% | -52.5% | ||
| Q3 24 | 323.0% | -62.1% | ||
| Q2 24 | 5.8% | -78.2% | ||
| Q1 24 | -20.8% | -63.1% |
资本支出强度CLFDCTMX
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 5.1% | 0.2% | ||
| Q4 24 | 7.0% | 0.2% | ||
| Q3 24 | 71.4% | 0.1% | ||
| Q2 24 | 2.5% | 0.4% | ||
| Q1 24 | 5.3% | 0.3% |
现金转化率CLFDCTMX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
